[The efficacy and safety analysis of endoscopic resection for infratemporal fossa benign mass].

Objective: To investigate the efficacy and safety of endoscopic resection of infratemporal fossa mass and to determine the indications for surgery. Methods: A retrospective case series study was conducted, including a total of 29 patients who underwent endoscopic surgery to treat infratemporal fossa mass in the Department of Rhinology of Beijing Tongren Hospital, Capital Medical University, from April 2008 to December 2021. Ten males and 19 females were included in the study, with age of (46.5±13.7) years. Pre-and post-operative sinus CT, sinus or nasopharyngeal enhanced MRI were evaluated, respectively. The main outcome measurements were the total resection of mass and the incidence of surgery-related complications. Results: Among the 29 cases of infratemporal fossa mass, 22 were schwannomas, 3 were cysts, 2 were neurofibromas, 1 was pleomorphic adenoma and 1 was basal cell adenoma. Preoperative imaging showed well-defined lesion boundaries, and postoperative pathology confirmed the benign nature of all cases. The endoscopic transnasal approach was used in 28 patients, while the combination of the transnasal approach and the transoral approach was used in 1 patient. Complete tumor removal was achieved in all cases with a 100% resection rate. The average follow-up time was 38 months (7-168 months), and no tumor recurrence was observed. Conclusions: The Endoscopic transnasal approach is a safe and effective surgical approach for the treatment of benign tumors or masses in the infratemporal fossa.

[The efficacy of hemostatic powder for chronic rhinosinusitis in endoscopic sinus surgery: a prospective, randomised, controlled and single blinded clinical trial].

Objective: To study the efficacy and patient comfort of absorbable hemostatic powder after endoscopic sinus surgery (ESS). Methods: A total of 21 (17 males, 4 females) patients with an average age of 42(ranging from 18 to 65) underwent bilateral ESS for chronic rhinosinusitis(CRS) in Beijing Tongren Hospital, Capital Medical University between October 2015 and July 2019 were enrolled to compare the effect of absorbable hemostasis powder with Nasopore using an intrapatient control design. A randomized controlled trial was conducted in the left and right nasal cavities of the same patient. If hemostatic powder was applied in the experiment nasal cavity, the Nasopore was applied in the control nasal cavity. The mean preoperative sinus computed tomography (CT) score was 6.25. All patients competed for symptom diaries using a visual analog scale (VAS, score out of 10) at baseline, through 1, 7, 14 and 30 days. Outcomes including bleeding, facial pain, nasal obstruction, nasal discharges using VAS were recorded separately for both sides. Postoperative endoscopic scores were also investigated. SPSS 22 and Graphpad prism 8.0 statistical softwares were used for the analysis. Paired t-test or nonparametric test was used between the test side and the control side. The difference was statistically significant (P<0.05). Results: The bleeding score and total nasal symptom VAS scores at postoperative days (POD) 1, 7, 14 and 30 were not significantly different(t=1.341, 0.552, 0.631, 0.158, all P>0.05;t=0.944, 1.471, 1.612, 2.251, all P>0.05). There was no significant difference between absorbable hemostasis powder and Nasopore side on POD 1, 7, 14 and 30 in terms of each nasal symptom VAS scores(all P>0.05). On POD 1, 7 and 14, the packing material degeneration scores of the absorbable hemostasis powder side were significantly lower than those of the Nasopore side [(1.33±0.21)vs(2.00±0.00),(0.38±0.18) vs (1.95±0.22), 0 vs (1.80±0.13), all P<0.01]. There were significant differences between absorbable hemostasis powder and Nasopore side on POD 1, 7, 14 and 30 in terms of endoscopic scores (edema, crusting, discharges, scar, polyps and material degeneration, t=3.07, 7.00, 6.41, 2.69, all P<0.05). Conclusions: The absorbable hemostasis powder and Nasopore has similar postoperative hemostasis effect. The absorbable hemostasis powder is rapidly cleared and without negative effects on mucosal wound healing 14 days postoperatively.

Identification of a novel HLA-A*33 allele, HLA-A*33:138.

HLA-A*33:138 differs from A*33:03:01 by a single nucleotide substitution at position 523 of exon 3.

Identification of a novel HLA-C*12 allele, HLA-C*12:221.

HLA-C*12:221 differs from C*12:02:03 by a single nucleotide substitution at position 367 of exon 3.

Identification of a new HLA-A allele, HLA-A*02:07:09, in a Chinese non-Hodgkin lymphoma patient.

HLA-A*02:07:09 is different from HLA-A*02:07:01 by a single nucleotide substitution at position 244.

Identification of a novel HLA-C*08 allele, HLA-C*08:01:20.

HLA-C*08:01:20 differs from C*08:01:01 by a single nucleotide substitution at position 93 of exon 2.

Identification of a novel HLA-DRB1*08 allele, HLA-DRB1*08:45:02.

HLA-DRB1*08:45:02 differs from DRB1*08:30:01 by a single nucleotide substitution at position 227 of exon 2.

Identification of a novel HLA-A*02 allele, HLA-A*02:622N.

HLA-A*02:622N differs from A*02:07:01 by a single nucleotide substitution at position 420 of exon 3.

Identification of a novel HLA-DRB1*07 allele, HLA-DRB1*07:01:19.

HLA-DRB1*07:01:19 differs from DRB1*07:01:01:01 by a single nucleotide substitution at position 261 of exon 2.

Identification of a novel HLA-C*15 allele, HLA-C*15:96Q.

HLA-C*15:96Q differs from C*15:02:01:01 by a single-nucleotide substitution at position 164 of exon 3.

Identification of a novel HLA-C*15 allele, HLA-C*15:02:21.

HLA-C*15:02:21 differs from C*15:02:01:01 by a single nucleotide substitution at position 105 of exon 2.

Identification of a novel HLA-DRB1*14 allele, HLA-DRB1*14:143, by sequence-based typing.

The novel HLA-DRB1*14:143 allele differs from DRB1*14:10 by two nucleotide substitutions at positions 344 and 345 of exon 2.

Identification of a novel HLA-A*02 allele, HLA-A*02:425, by sequence-based typing.

The novel HLA-A*02:425 allele differs from A*02:121 by a single nucleotide substitution at position 601 of exon 3.

Identification of a novel HLA-DRB1*14 allele, HLA-DRB1*14:143, by sequence-based typing.

The novel HLA-DRB1*14:143 allele differs from DRB1*14:10 by two nucleotide substitutions at positions 344 and 345 of exon 2.